Use of Molecular Imaging to Differentiate Neuroendocrine Tumors from Other Synchronous Primary Cancers: A Case Series Abstract #761

Introduction: Approximately 22% of neuroendocrine tumors (NET) co-exist with other cancers.
Aim(s): To identify the role of combination of molecular imaging studies for detection of, synchronous to NETs, common cancers and/or differentiate the origin of metastatic tumor lesions.
Materials and methods: Seven patients with NETs and other primaries, histologically proven, were included and had cross-sectional imaging, 68Gallium (Ga) -DOTATATE and 2-fluoro-2-deoxy-D-glucose (FDG) PET studies.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Vincent Cheung
Keywords: NET, synchronous, PET, Gallium, FDG

To read results and conclusion, please login ...

Further abstracts you may be interested in

#758 Cardiac Metastases in Neuroendocrine Tumors- Diagnosis, Management and Outcomes
Introduction: Common areas of metastases in neuroendocrine tumors (NET) include liver, lymph nodes and bone. Limited data are available for cardiac metastases (CM).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: DR Vincent Cheung
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#863 Assessment of Neuroendocrine Tumors' Heterogeneity with Combination of Molecular Imaging Studies
Introduction: Neuroendocrine tumors (NET) are heterogeneous neoplasms. The choice of the appropriate molecular imaging study for assessment of disease extent usually depends on tumor grade.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Roberta E Rossi
#2959 Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
Introduction: The simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Paola Mapelli
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann